SAFETY AND EFFICACY AT 48 WEEKS AFTER SWITCHING FROM TENOFOVIR DISOPROXIL FUMARATE (TDF) TO TENOFOVIR ALAFENAMIDE (TAF) IN CHRONIC HBV PATIENTS WITH RISK FACTORS FOR TDF USE

被引：0

作者：

Buti, Maria ^{[1
,2
]}

Lampertico, Pietro ^{[3
]}

Lim, Young-Suk ^{[4
]}

Agarwal, Kosh ^{[5
]}

Fung, Scott K. ^{[6
]}

Tsang, Owen ^{[7
]}

Elkhashab, Magdy ^{[8
]}

Kao, Jia-Horng ^{[9
]}

Luis Calleja, Jose ^{[10
]}

Khalili, Mandana ^{[11
]}

Ravendhran, Natarajan ^{[12
]}

Tan, Susanna ^{[13
]}

Flaherty, John F. ^{[13
]}

Gaggar, Anuj ^{[13
]}

Lau, Audrey H. ^{[13
]}

Wu, George ^{[13
]}

Hann, Hie-Won L. ^{[14
]}

Pan, Calvin ^{[15
]}

Kim, Hyung Joon ^{[16
]}

Kennedy, Patrick T. F. ^{[17
]}

Chan, Henry Lik Yuen ^{[18
]}

机构：

[1] Hosp Gen Univ Valle Hebron, Barcelona, Spain

[2] Ciberehd, Barcelona, Spain

[3] Univ Milan, Gastroenterol & Hepatol, Fdn Irccs Ca Granda O Maggiore Policlin, Milan, Italy

[4] Univ Ulsan, Dept Gastroenterol, Ctr Liver, Asan Med Ctr,Coll Med, Ulsan, South Korea

[5] Kings Coll Hosp London, Inst Liver Studies, London, England

[6] Univ Hlth Network, Toronto Gen Hosp, Toronto Ctr Liver Dis, Toronto, ON, Canada

[7] Princess Margaret Hosp, Kwai Chung, 2-10 Princess Margaret Hosp Rd, Hong Kong, Peoples R China

[8] Toronto Liver Ctr, Res, Toronto, ON, Canada

[9] Natl Taiwan Univ, Grad Inst Clin Med, Coll Med, Taipei, Taiwan

[10] Hosp Univ Puerta De Hierro, Majadahonda, Spain

[11] Univ Calif San Fransisco, San Francisco, CA USA

[12] Digest Dis Associates, Wyomissing, PA USA

[13] Gilead Sci Inc, 353 Lakeside Dr, Foster City, CA 94404 USA

[14] Thomas Jefferson Univ Hosp, Philadelphia, PA 19107 USA

[15] Calvin Q Pan Clin, New York, NY USA

[16] Chung Ang Univ, Coll Med, Seoul, South Korea

[17] Barts Hlth NHS Trust, London, England

[18] Chinese Univ Hong Kong, Hong Kong, Peoples R China

来源：

HEPATOLOGY | 2019年 / 70卷

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

476

引用

页码：301A / 301A

页数：1

共 50 条

[21] A phase 3 study of tenofovir alafenamide (TAF) compared with tenofovir disoproxil fumarate (TDF) in patients with HBeAg-positive chronic HBV (CHB): Week 48 efficacy and safety results
Strasser, S.
Roberts, S.
Angus, P.
Chan, H. L. Y.
Fung, S.
Seto, W. K.
Chuang, W. L.
Chen, C. Y.
Kim, H. J.
Hui, A. J.
Janssen, H. L. A.
Chowdhury, A.
Tsang, T. Y. O.
Mehta, R.
Gane, E.
Flaherty, J. F.
Massetto, B.
Kitrinos, K.
Dinh, P.
Subramanian, G. M.
Mchutchison, J. G.
Lim, Y. S.
Acharya, S. K.
Agarwal, K.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2016, 31 : 82 - 82
[22] The Effect of Switching from Tenofovir Disoproxil Fumarate (TDF) to Tenofovir Alafenamide (TAF) on Liver Enzymes, Glucose, and Lipid Profile
Squillace, Nicola
Ricci, Elena
Menzaghi, Barbara
De Socio, Giuseppe Vittorio
Passerini, Simone
Martinelli, Canio
Mameli, Maria Sabrina
Maggi, Paolo
Falasca, Katia
Cordier, Laura
Celesia, Benedetto Maurizio
Salomoni, Elena
Di Biagio, Antonio
Pellicano, Giovanni Francesco
Bonfanti, Paolo
DRUG DESIGN DEVELOPMENT AND THERAPY, 2020, 14 : 5515 - 5520
[23] IMPACT OF COADMINISTRATION WITHOUT OR WITH FOOD ON THE 96-WEEK EFFICACY AND SAFETY OF TENOFOVIR ALAFENAMIDE (TAF) IN VIRALLY SUPPRESSED CHRONIC HBV PATIENTS SWITCHED FROM TENOFOVIR DISOPROXIL FUMARATE (TDF) TO TAF
Kao, Jia-Horng
Chuang, Wan-Long
Chen, Chi-Yi
Ahn, Sang Hoon
Fung, Scott K.
Elkhashab, Magdy
Hann, Hie-Won L.
Ravendhran, Natarajan
Nguyen, Tuan T.
Tan, Susanna
Flaherty, John F.
Gagger, Anuj
Gao, Bing
Brainard, Diana M.
Phan, Charles G.
Lim, Young-Suk
Ferret, Maria Asuncion Buti
Lampertico, Pietro
HEPATOLOGY, 2020, 72 : 484A - 484A
[24] A PHASE 3 STUDY COMPARING SWITCHING FROM TENOFOVIR DISOPROXIL FUMARATE (TDF) TO TENOFOVIR ALAFENAMIDE (TAF) WITH CONTINUED TDF TREATMENT IN VIROLOGICALLY-SUPPRESSED PATIENTS WITH CHRONIC HEPATITIS B (CHB): WEEK 48 EFFICACY AND SAFETY RESULTS
Chan, Henry Lik Yuen
Lampertico, Pietro
Buti, Maria
Fung, Scott
Ahn, Sang Hoon
Chuang, Wan-Long
Tak, Won Young
Ramji, Alnoor
Chen, Chi-Yi
Tam, Edward
Bae, Ho
Ma, Xiaoli
Flaherty, John
Gaggar, Anuj
Lau, Audrey
Feierbach, Becket
Wu, George
Suri, Vithika
Subramanian, Mani
Huy Trinh
Yoon, Seung-Kew
Agarwal, Kosh
Lim, Young-Suk
GUT, 2019, 68 : A142 - A143
[25] FACTORS ASSOCIATED WITH A LACK OF VIRAL SUPPRESSION IN CHRONIC HBV ( CHB) PATIENTS AFTER 8 YEARS OF TREATMENT WITH TENOFOVIR ALAFENAMIDE ( TAF) OR TENOFOVIR DISOPROXIL FUMARATE ( TDF) FOLLOWED BY TAF TREATMENT
Gane, Edward J.
Buti, Maria
Fung, Scott K.
Chan, Henry Lik Yuen
Izumi, Namiki
Chuang, Wan Long
Ahn, Sang Hoon
Mehta, Rajiv M.
Gurel, Selim
Abramov, Frida
Yee, Leland J.
Wang, Hongyuan
Mateo, Roberto
Flaherty, John F.
Ma, Xiaoli
Pan, Calvin Q.
Lim, Young-Suk
Marcellin, Patrick
HEPATOLOGY, 2023, 78 : S519 - S520
[26] Switching from a tenofovir disoproxil fumarate (TDF)-based regimen to a tenofovir alafenamide (TAF)-based regimen: data in virologically suppressed adults through 48 weeks of treatment
Mills, Tony
Andrade, Jamie
Diperri, Giovanni
Van Lunzen, Jan
Koenig, Ellen
Elion, Richard
Cavassini, Matthias
Madruga, Jose Valdez
Brunetta, Jason
Shamblaw, David
Dejesus, Edwin
Cohen, Calvin
Plummer, Andrew
Liu, Yapei
McCallister, Scott
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2015, 18
[27] Bone and renal safety are improved in chronic HBV patients switched to tenofovir alafenamide (TAF) after either 2 or 3 years of prior tenofovir disoproxil fumarate (TDF) treatment
Buti, Maria
Izumi, Namiki
Lim, Young-Suk
Janssen, Harry
Kao, Jia-Horng
Streinu-Cercel, Adrian
Nurmukhametova, Elena
Ma, Xiaoli
Fehmi, Tabak
Jablkowski, Maciej
Suri, Vithika
Flaherty, John F.
Lau, Audrey
Gaggar, Anuj
Mo, Shuyuan
Chaudhuri, Abhijit
Fung, Scott
Chuang, Wan-Long
Gane, Edward
JOURNAL OF HEPATOLOGY, 2019, 70 (01) : E457 - E458
[28] Switching Tenofovir Disoproxil Fumarate (TDF) to Tenofovir Alafenamide Fumarate (TAF) in Hepatitis B/HIV Co-Infection: A Feasibility Study
Lok, James
Veloz, Maria Fernanda Guerra
Byrne, Ruth
Carey, Ivana
Childs, Kate
Agarwal, Kosh
Nelson, Mark
CLINICAL THERAPEUTICS, 2024, 46 (02) : 159 - 163
[29] Eligibility of patients in a community HIV setting for switching rilpivirine/emtricitabine/tenofovir disoproxil fumarate (R/F/TDF) to tenofovir alafenamide(TAF)
Goorney, B.
Perez, K.
HIV MEDICINE, 2019, 20 : 39 - 39
[30] TENOFOVIR ALAFENAMIDE (TAF) COMPARED WITH TENOFOVIR DISOPROXIL FUMARATE (TDF) IN PATIENTS WITH CHRONIC HBV: WEEK 96 EFFICACY AND SAFETY RESULTS IN CHINESE PATIENTS ENROLLED IN 2 GLOBAL PHASE 3 STUDIES
Chan, Henry Lik-Yuen
Seto, Wai Kay
Fung, Scott
Hou, Jinlin
Pan, Calvin
Chuang, Wan-Long
Chang, Ting-Tsung
Hui, Aric-Josun
Chen, Chi-Yi
Tsang, Tak Yin Owen
Yang, Jenny
Flaherty, John
Gaggar, Anuj
Mo, Shuyuan
Kao, Jia-Horng
GUT, 2018, 67 : A302 - A302

← 1 2 3 4 5 →